ELVN Q3 2022 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$11M

Net Income

-$11M

EPS (Diluted)

$-0.70

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$91M

Total Liabilities

$9M

Stockholders' Equity

$82M

Cash & Equivalents

$86M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$24,000	+100.0%
Operating Income	-$11M	-$14M	+20.0%
Net Income	-$11M	-$14M	+22.7%